Ignite Creation Date:
2025-12-25 @ 3:52 AM
Ignite Modification Date:
2026-03-14 @ 5:09 AM
Study NCT ID:
NCT06082102
Status:
RECRUITING
Last Update Posted:
2025-09-15
First Post:
2023-10-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ICP-CL-00123
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None